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Background and Purpose: Elevation of serum cardiac troponin T (cTnT) is regarded as a specific marker of acute 
coronary syndrome. Serum cTnT can be increased in patients with acute ischemic stroke, but its clinical implications 
remain unclear. The aim of this study was to identify the relationships between elevated cTnT and stroke severity, 
location, and prognosis.
Methods: From January 2005 to December 2006, this study recruited 455 consecutive patients who were admitted 
to Kangbuk Samsung Hospital due to acute ischemic stroke within 3 days of onset, which was confirmed by diffusion 
magnetic resonance imaging. A total of 416 patients was finally included and divided into 2 groups: an elevated cTnT 
group (n=45) and a normal cTnT group (n=371). The short-term prognosis was assessed by 30-day modified Rankin 
Scale responder analysis was compared between the two groups.
Results: Serum cTnT was elevated in 10.8% of cases, with elevated cTnT associated with greater stroke severity, 
as assessed by the National Institutes of Health Stroke Scale score, Insular-lobe involvement was more common in 
patients with elevated cTnT than in the normal cTnT group. Short-term prognosis was more unfavorable in the 
elevated cTnT group than in  the normal cTnT group. Multivariate regression analysis indicated that elevated cTnT 
was independently related to insular involvement, cardioembolism, and unfavorable outcome.
Conclusions: Elevated cTnT in acute ischemic stroke was associated with severe neurological deficits at stroke 
onset and damages to the insular lobe. The outcome of acute ischemic stroke was worse for patients with elevated 
cTnT than for those with normal cTnT. The pathomechanism underlying acute ischemic stroke and subclinical 
myocardial damage warrants further study.
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INTRODUCTION
Stroke is one of major causes of death and dis-
ability in Western countries and in Korea. Due to the 
high mortality and morbidity rates associated with 
stroke, it is becoming a major community health 
problem worldwide. The association between heart Journal of Clinical Neurology: Vol. 4, No. 2, 2008
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disease and acute stroke is established.
1 Cardiac sequelae, 
including myocytolysis, serum enzyme elevation, and 
arrhythmia, are known to develop in some ischemic 
stroke patients.
2-6 The brain-heart connection was 
described early in the 20
th century when Levy showed 
that changes in central nervous system metabolism 
influences cardiac function.
7  Several studies have found 
that the levels of creatinine kinase–MB fraction (CK- 
MB) and lactate dehydrogenase were elevated in 8-15% 
of patients with acute stroke,
8,9  and that elevated levels 
of serum troponin T are found in 10-34% of patients 
with acute stroke.
10-13 Serum cardiac troponin T (cTnT) 
is a new biochemical marker of myocardial damage 
with high specificity and sensitivity. There is conside-
rable clinical and experimental evidence that cardiac 
changes in ischemic stroke result from excessive sym-
pathetic nervous activity secondary to insular cortical 
damage.
14 Several mechanisms can result in elevated 
concentrations of serum cTnT during the early phase 
of ischemic stroke, such as primary myocardial damage 
with secondary cardioembolic cerebral ischemia or 
primary cerebral ischemia, with secondary myocardial 
injury attributable to central activation of the sym-
pathoadrenal system.
9,15,16 Acute ischemic cerebrovas-
cular events can induce various myocardial changes. 
Diffuse myocardial damage characterized by micro-
islands of necrosis and subendocardial hemorrhage 
can occur after stroke.
8,17-21 This type of injury is called 
myocytolysis, and it occurs as a result of intense 
activation of the sympathetic nervous system. A 
potential primary focus of myocytolysis is presumed 
to be its extensive autonomic and limbic connection.
22,23
The aims of our study were to (1) identify the 
relationship between elevated serum cTnT and stroke 
severity, (2) determine the relationship between elevated 
serum cTnT and insular involvement, and (3) elucidate 
the influence of elevated serum cTnT on the prognosis 
associated with ischemic stroke.
MATERIALS AND METHODS
We identified 455 consecutive patients from a stroke 
database who were admitted to Kangbuk Samsung 
Hospital with a diagnosis of ischemic stroke between 
January 2005 and December 2006. The inclusion 
criteria were (1) acute cerebral infarction confirmed 
by brain diffusion-weighted imaging (DWI) magnetic 
resonance imaging (MRI) within 3 days of stoke onset; 
(2) measurement of serum cTnT level (≥0.01 ng/mL), 
and electrocardiography (ECG) and echocardiography 
performed within 3 days of stoke onset; and (3) a 
clear description of neurological scales. The exclusion 
criteria were (1) any recent ischemic heart disease, 
defined as previous myocardial infarction (AMI; 
American College of Cardiology/American Heart 
Association [ACC/AHA] criteria) within 2 weeks prior 
to and 3 days after stroke onset; (2) symptoms suggestive 
of AMI or unstable angina before admission; (3) 
newly developed pathologic Q waves on admission 
ECG; (4) previous coronary angioplasty or coronary 
bypass surgery; and (5) other heart diseases and debili-
tating diseases with the possibility of serum cTnT 
elevation, such as congestive heart failure, valvular 
heart disease (VHD), and end-stage renal disease 
(ESRD). The criteria for acute, evolving or recent 
AMI were defined by the ACC/AHA
24 as the elevation 
of biochemical markers of myocardial necrosis (pre-
ferably troponin) with at least one of the following: 
(1) ischemic symptoms, (2) development of patho-
logic Q waves on the ECG, (3) ECG changes in-
dicative of ischemia (ST segment elevation [≥1 mm] 
or depression [≥0.5 mm]), and (4) coronary artery 
intervention (e.g., coronary angioplasty). Serum cTnT 
was measured as a part of routine laboratory testing 
on admission to exclude subclinical coronary events. 
The presence of intracerebral or subarachnoid hemorrhage 
was ruled out by computed tomography at the time 
of admission. Thus, the study population comprised 
patients with acute ischemic stroke but without known 
or overt new ischemic heart disease. Information 
regarding heart disease symptoms, cardiac history, and 
risk factors for cardiovascular disease were obtained 
from the patients’ medical records. Serum cTnT was 
measured from venous blood samples using the Elecsys 
2010 platform (Roche Diagnostics, Mannheim, Germany). 
The cut-off value for elevated serum cTnT was set at 
0.01 ng/mL. Twelve-lead ECG was performed imme-Song HS, et al. Cardiac Troponin T Elevation After Stroke: Relationships Between Elevated Serum Troponin T, Stroke Location, and Prognosis
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(A)                                                 (B)
Figure 1. Diffusion-weighted magnetic resonance imaging (MRI) (A) and T2-weighted MRI (B) of a 68-year-old woman, 
showing an ischemic stroke involving the right insular lobe.
diately on admission. Of the original cohort, 39 patients 
were excluded for the following reasons: diagnosis of 
transient focal neurologic deficits (7 patients), cTnT 
measurement performed after 3 days of stroke onset 
(9 patients), cardiac problems and debilitating medical 
disease (16 patients with AMI, 3 with VHD, and 2 with 
ESRD), and incomplete medical records (2 patients). 
Blood pressures and pulse rates were measured imme-
diately upon presentation at the emergency room. MRI 
was performed on a 1.5-T whole-body scanner (Intera 
Zyroscan; Philips Medical System, The Netherlands). 
Single-shot echo planar DWI imaging was performed 
with a repeat time of 7,500 ms, an echo time of 99.3 ms, 
a field of view of 22×22 cm, matrix of 128×128 cm, 
a slice thickness of 5 mm with a 1-mm gap, 23 axial 
slices, and b values of 0 s/mm
2 and 1,000 s/mm
2, with 
6 gradient directions and 3 averages. Acute cerebral 
infarction was characterized by regions of increased 
signal intensity on DWI and decreased signal intensity 
on apparent diffusion coefficient maps. Acute infarctions 
on DWI were outlined manually on a slice-by-slice 
basis by a neuroradiologist and neurologist who were 
blinded to the clinical data. Insular involvement was 
defined as regions that involved the right or left 
insular cortex (posterior, superior, and medial areas; 
Fig. 1). To evaluate the clinical outcome in each 
patient, we applied a responder analysis that defined 
favorable outcomes at 30 days (and not 90 days) as 
influenced by the baseline National Institutes of 
Health Stroke Scale (NIHSS). Favorable outcome was 
defined using the following criteria: a 30-day modified 
Rankin Scale (mRS) score of 0 if the baseline NIHSS 
score was <8, an mRS score of 0 or 1 if the NIHSS 
score was 8-14, and an mRS score 0-2 if the NIHSS 
score was >14.
25 Patients with an unfavorable outcome 
were defined as those not fulfilling the favorable- 
outcome criteria. The pathogenesis of stroke was classi-
fied by the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) classification.
26,27
Categorical and continuous variables were compared 
by the chi-square test and Student’s t-test, respectively. 
Univariate and multivariate logistic regression was used 
for further analysis. The cut-off for statistical signifi-
cance was set at p value of 0.05. Analyses were 
performed with SPSS for Windows (version 12.0, 
Chicago, IL, USA).
RESULTS
A total of 416 patients with acute stroke, as confirmed 
by DWI within 72 h of stroke onset, were enrolled Journal of Clinical Neurology: Vol. 4, No. 2, 2008
- 78 -
Table 1. Epidemiologic and clinical characteristics of patients with elevated and normal serum cTnT
Variable
Elevated cTnT
a
(n=45)
Normal cTnT
a
(n=371)
p
Age (years)  72.46±5.37  66.07±4.82 0.058
Male 24 (53.3) 208 (56.1) 0.756
Time to admission (hours)   9.25±2.75    9.5±2.45 0.849
Medical history
Hypertension 31 (68.9) 213 (57.4) 0.425
Diabetes mellitus 16 (35.6) 141 (38.0) 0.561
Atrial fibrillation 13 (28.9)  62 (16.7) 0.032*
Dyslipidemia 17 (37.8)  92 (24.8) 0.041*
Previous stroke history 10 (22.2)  72 (19.4) 0.659
Previous MI history  7 (15.6)  53 (14.3) 0.514
Current smoker 26 (57.8) 211 (56.9) 0.732
Pulse (beat/minute)  92.43±23.16  87.97±31.55 0.441
Systolic BP (mmHg) 168.82±22.13 159.65±25.23 0.326
Diastolic BP (mmHg) 106.51±8.33 110.74±20.36 0.517
Infarct location
Right MCA territory  5 (11.1)  44 (11.9) 0.746
Left MCA territory  9 (20.0)  58 (15.6) 0.425
Insular involvement 13 (28.9)  56 (15.1) 0.042*
Right insular lobe  5 (11.1)  23 (6.2) 0.214
Left insular lobe  8 (17.8)  33 (8.9) 0.187
Bilateral ACA territory  2 (4.4)   7 (1.9) 0.091
Bilateral PCA territory  2 (4.4)  14 (3.8) 0.542
Deep penetrating infarction  8 (17.8) 138 (37.2) 0.041*
Brainstem 12 (26.7)  79 (21.3) 0.211
Cerebellum  2 (4.4)  26 (7.0) 0.497
Multiple territorial infarction  5 (11.1)   5 (1.3) 0.032*
TOAST classification
Large-artery atherosclerosis 14 (31.1) 153 (41.2) 0.061
Cardioembolism 20 (44.4)  54 (14.6) 0.017*
Small-vessel occlusion  4 (8.9)  81 (21.8) 0.041*
Stroke of other determined etiology  0 (0)   8 (2) 0.132
Stroke of undetermined etiology  7 (15.6)  75 (20.2) 0.218
ACA; anterior cerebral artery, BP; blood pressure, MCA; middle cerebral artery, PCA; posterior cerebral artery, cTnT; 
serum cardiac troponin T, MI; myocardial infarction, TOAST; Trial of Org 10172 in Acute Stroke Treatment. 
Statistical comparison between elevated and normal cTnT groups was performed only in each subset and the total study 
population.
aData are n (%) or mean±SD values.
*Significant (p<0.05) difference between groups.
in this study. Serum cTnT was elevated in 10.8% 
(45/416) of the acute ischemic stroke patients. The 
416 patients were divided into 2 groups according to 
serum cTnT levels: an elevated cTnT group (≥0.01 
ng/mL) and a normal cTnT group (<0.01 ng/mL).
1. Comparison of the location and type of stroke 
between patients with elevated and normal serum 
cTnT
Epidemiologic and clinical characteristics were com-
pared between the elevated and normal serum cTnT 
groups. Patients in the elevated serum cTnT group 
had a higher prevalence of atrial fibrillation and Song HS, et al. Cardiac Troponin T Elevation After Stroke: Relationships Between Elevated Serum Troponin T, Stroke Location, and Prognosis
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Table 2. Comparison of the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores 
between patients with elevated and normal serum cTnT
Variable
Elevated cTnT
(n=45)
Normal cTnT
(n=371)
p
NIHSS score
Admission 11  (8-38) 9  (6-22)
Day 7  9 (6-29) 8 (4-20)
Day 30  8 (7-18) 5 (3-14)
mRS
Day 1  4 (2-5) 3 (2-5)
Day 7  3 (2-5) 2 (1-4)
Day 30  3 (1-4) 2 (1-4)
Favorable outcome
†  3/45 (6.7%)  72/371 (19.4%) 0.015*
Unfavorable outcome
† 42/45 (93.3%) 299/371 (80.5%) 0.036*
Values are medians and interquartile ranges.
*Significant (p<0.05) difference between groups.
†Defined according to 30-day mRS responder analysis.
Table 3. Univariate analysis for variables associated with elevated serum cTnT
Variables
Odds ratio
(95% confidence interval)
p
Age (per 5.2 years) 1.21 (0.82–1.63) 0.133
Sex (male) 0.86 (0.66–1.49) 0.253
Time to admission (1.7 hours) 0.64 (0.31–1.04) 0.341
Pulse (per 12.1/minute) 1.07 (0.61–1.51) 0.337
Systolic BP (per 10.9 mmHg) 1.29 (0.75–1.82) 0.175
Diastolic BP (per 8.0 mmHg) 1.16 (0.64–1.65) 0.251
Infarct location (presence)
Right MCA territory 0.85 (0.46–1.24) 0.129
Left MCA territory 0.76 (0.39–1.17) 0.242
Insular involvement 2.83 (2.11–3.52) 0.021*
Right Insular lobe 1.22 (0.72–1.89) 0.189
Left Insular lobe 1.47 (0.95–1.96) 0.147
Brainstem 1.85 (1.15–2.46) 0.038*
Multiple territorial infarction 1.74 (1.01–2.35) 0.047*
TOAST classification
Large-artery atherosclerosis 1.86 (1.17–2.49) 0.045*
Cardioembolism 2.71 (2.23–3.25) 0.011*
Small-vessel occlusion 0.96 (0.46–1.23) 0.306
Stroke of undetermined etiology 0.78 (0.35–1.24) 0.494
Unfavorable outcome
† 2.63 (1.74–3.41) 0.016*
Continuous variables like age, time to admission, pulse, systolic blood pressure, and diastolic blood pressure were 
categorized according to their standard deviation values during logistic regression analysis (Age: 5.2 years, Time to 
admission: 1.7 hours, pulse: 12.1/minute, systolic BP: 10.9 mmHg, diastolic BP: 10.9 mmHg).
*Significant (p<0.05) difference between groups.
†According to 30-day mRS responder analysis.
dyslipidemia than the normal serum cTnT group; they 
were also more likely to have multiple territorial 
infarctions and cardioembolism, but less likely to have 
deep penetrating artery infarction and, by TOAST 
classification, small vessel disease. Insular involvement 
was more common in the elevated serum cTnT group Journal of Clinical Neurology: Vol. 4, No. 2, 2008
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Figure 2. Levels of serum cardiac troponin T (cTnT in the elevated cTnT group, n=45).
Table 4. Multivariate analysis for variables independently associated with elevated serum cTnT 
Variables
Odds ratio
(95% confidence interval)
p
Location
Insular involvement 2.59 (1.89–3.16) 0.034*
Brain-stem 1.62 (1.15–2.24) 0.063
Multiple territorial infarction 1.48 (0.78–1.99) 0.059
Large-artery atherosclerosis 1.42 (0.85–2.02) 0.072
TOAST classification 
Cardioembolism 2.51 (1.77–3.19) 0.037*
Unfavorable outcome
† 2.42 (1.89–2.96) 0.025*
*Significant (p<0.05) difference between groups.
†According to 30-day mRS responder analysis.
than in the normal serum cTnT group (56/371 [15.1%] 
vs. 13/45 [28.9%], p=0.042), but hemispheric laterality 
of insular involvement was not evident (Table 1).
2. Comparison of severity and prognosis between 
patients with elevated and normal serum cTnT
We compared stroke severity using the criterion of 
NIHSS score on the 1
st day of admission. The stroke 
severity in the elevated serum cTnT group was greater 
and the disability was more severe (mRS on the 1
st 
day) than in the normal serum cTnT group. The short- 
term prognosis (30 days) was estimated by comparing 
the improvement using 30-day mRS responder analysis.
25 
The outcome was more favorable in the elevated 
serum cTnT group than in the normal serum cTnT 
group (3/45 [6.7%] vs. 72/371 [19.4%], p=0.015; Table 
2). The univariate analysis showed that the elevated 
serum cTnT group was significantly associated with 
insular-lobe involvement, brainstem infarction, multiple 
territorial infarctions, cardioembolism and large-artery 
atherosclerosis, and unfavorable outcome (Table 3). 
Separate analysis of those variables identified in the 
univariate analysis for the independent association 
with elevated serum cTnT by multivariate analysis 
indicated that only insular-lobe involvement, cardio-
embolic stroke and unfavorable outcome were indepen-
dently related to elevated serum cTnT (Table 4).Song HS, et al. Cardiac Troponin T Elevation After Stroke: Relationships Between Elevated Serum Troponin T, Stroke Location, and Prognosis
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Table 5. Abnormal findings on cardiologic evaluations in the elevated and normal serum cTnT groups
Elevated cTnT
a
(n=45) 
Normal cTnT
a
(n=371)
p
Electrocardiogram
†
> 1 mm ST depression  5 (11.1) 21 (5.7) 0.024*
> 0.5 mm ST elevation  0 (0)  0 (0)
Pathologic Q wave  3 (6.6)  0 (0) 0.019*
Increased cardiac enzyme 
CK-MB
25 (55.6) 22 (5.9) 0.011*
Echocardiogram
Focal wall hypokinesia  6 (13.3)  0 (0) 0.006*
Global hypokinesia  2 (4.4)  0 (0) 0.008*
Decreased ejection fraction  9 (20.0) 12 (3.2) 0.042*
aData are n (%) values.
*Significant (p<0.05) difference between groups.
Statistical comparison between elevated and normal cTnT groups was performed only in each subset and the total study 
population.
†According to ACC/AHA guidelines, ≥ 0.5-mm ST depression or ≥ 1-mm ST elevation in two or more contiguous leads 
was defined as an electrical abnormality. CK-MB, serum creatine kinase MB.
Levels of serum cTnT were less than 0.1 ng/mL 
in 91.1% of patients in the elevated cTnT group; 
they were more than 0.1 ng/mL in four (8.9%) of 
these patients, and the highest serum cTnT level in 
this group was 0.266 ng/mL (Fig. 2). Abnormalities 
on cardiologic evaluations including ECG, serum 
CK-MB, and echocardiogram were more frequent in 
the elevated serum cTnT group than in the normal 
serum cTnT group (Table 5).
DISCUSSION
Elevated serum cTnT was detected in 10.8% of 
the acute ischemic stroke patients that we examined, 
and was related to unfavorable outcomes 30 days after 
ischemic stroke. One of the novel findings of this study 
is that elevated serum cTnT in patients with ischemic 
stroke might be associated with stroke location and 
unfavorable outcome.
Every stroke is likely to exert considerable stress 
on the patient’s heart. Elevated serum cTnT might be 
indicative of a lower cardiac tolerance to stress caused 
by the acute ischemic stroke. This is possible explanation 
for the relationship between elevated serum cTnT and 
the poor short-term prognosis found in this study. 
Previous studies have suggested that cardiac damage 
after ischemic stroke is associated with sympathoadrenal 
activation.
14,20 Epinephrine and cortisol concentrations 
are elevated after a stroke and higher concentrations 
have been reported in association with myocardial 
damage.
10 In the present study, elevated serum cTnT 
level was associated with severe stroke and insular- 
lobe damage, regardless of laterality, which can cause 
severe stress and lead to sympathoadrenal activation.
This study demonstrates that there is a relationship 
between elevated serum cTnT and stroke with insular 
cortex involvement. Sensory, autonomic, and limbic 
functions are integrated in the insula through reciprocal 
connections with principle sensory areas, paralimbic 
areas in the orbital, temporopolar and cingulate cortices, 
and the hypothalamus. Stimulation of the insula in 
rats as well as in humans undergoing surgery for epilepsy 
has demonstrated that this brain area is involved in 
cardiac autonomic control.
13,28,29 The short-term outcome 
is less favorable and the stroke is more severe in 
stroke patients with elevated serum cTnT than in 
those with normal serum cTnT levels. Cardioembolic 
stroke was more common in patients with elevated 
serum cTnT. Doctors in charge of stroke units should 
be more prudent when dealing with these patients 
and should offer cardiologic evaluations and secondary Journal of Clinical Neurology: Vol. 4, No. 2, 2008
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prevention measures, and also investigations for stroke 
risk factors and proper interventions for coronary 
artery disease. When excluding patients with obvious 
cardiac damage from the study population, patients 
in the elevated serum cTnT group (0.16±0.15 μg/L, 
mean±SD) did not satisfy the clinical, ECG or echo-
cardiographic criteria for AMI (ACC/AHA criteria). 
The ST segment elevations and depressions were not 
prominent enough to meet the criteria for AMI as 
defined by the ACC/AHA. Two of patients had 
developed pathologic Q waves since their previous 
ECG, which had been taken more than 6 months 
before that performed for the current study. None of 
the patients in the elevated serum cTnT group had 
chest pain. These findings might be attributable to 
serum cTnT being a more sensitive for indicator of 
myocardial damage. However, the elevation of serum 
cTnT might be related to underlying coronary artery 
disease exacerbated by the stress of an acute ischemic 
stroke. Our study was subject to several limitations. 
First, we relied on single baseline blood samples and 
did not retest serum cTnT so as to determine trends 
in the cTnT level, and thus we were unable to account 
for variations in serum cTnT levels that might have 
occurred over time. Repeated assays could provide 
additional information on the development and evolution 
of myocardial damage in patients with acute ischemic 
stroke. Second, we did not measure the concentrations 
of epinephrine, norepinephrine and cortisol as indirect 
markers of sympathoadrenal activation, which might 
have provided further information on the tone of the 
sympathetic nervous system. Third, our study was 
unable to assess the long-term prognosis in normal 
and elevated serum cTnT groups due to the short 
follow-up period. Despite these limitations, the findings 
of this study will improve the understanding of the 
implications of serum cTnT elevation in acute ischemic 
stroke. We suggest that clinicians should consider 
adding a serum cTnT titer to their routine admission 
testing in patients with suspected ischemic stroke, 
since a high serum cTnT level appears to be related 
to a significantly higher risk for worse outcomes and 
cardiac complications. Information on serum cTnT 
might also provide clues as to the location and extent 
of ischemic stroke.
In summary, elevated serum cTnT concentration 
without evidence of myocardial lesion was found in 
10.8% of the acute ischemic stroke patients that we 
examined. Stroke severity (as assessed by the NIHSS 
and mRS) and insular-lobe involvement were associated 
with increased serum cTnT levels. Patients with elevated 
serum cTnT levels during acute ischemic stroke 
treatment showed worse outcomes than those with 
normal serum cTnT levels. Serial serum cTnT assess-
ment and long-term clinical outcome data in a larger 
study population are needed in future studies in order 
to clarify the clinical implications of elevated serum 
cTnT levels in acute ischemic stroke.
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